Dr Reddy’s Laboratories is also working on a generic version of Wegovy. (Image/Getty) US pharma major Eli Lilly on Thursday launched its global bestseller anti-obesity and diabetes drug Mounjaro ...

US pharma major Eli Lilly on Thursday launched the much-awaited diabetes and obesity management drug Mounjaro in India at one-fifth of US price. Lilly launched the drug in a single dose vial following ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, March 20, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country ...

Tirzepatide was evaluated in two robust global clinical development programs. (Image Credits: Pexels) Eli Lilly and Company (India) on Thursday announced the launch of Mounjaro in single-dose vial ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the US-based drug company as India, world's most populous country ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In a fresh appearance on CNBC’s Squawk on the Street ...

Here are his latest remarks about Eli Lilly and Company (NYSE:LLY): “Keep an eye on Lilly. Because these have to bounce. If they bounce. . .” “Remember Lilly passed Tesla, that’s why ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In a fresh appearance on CNBC’s Squawk on the Street, Jim ...

If you know that doing something is bad for you, why would you wilfully do it anyway? I often ask myself this when I’m in the middle of yet another doom-scrolling session on my phone. Join ST's ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).